Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Vivos Therapeutics, Inc. (VVOS)
Company Research
Source: Yahoo! Finance
All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 7.7%. Earnings per share (EPS) exceeded analyst estimates by 39%. Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Healthcare industry in the US. Performance of the American Healthcare industry. The company's shares are down 8.1% from a week ago. You still need to take note of risks, for example - Vivos Therapeutics has 5 warning signs (and 3 which can't be ignored) we think you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitu
Show less
Read more
Impact Snapshot
Event Time:
VVOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VVOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VVOS alerts
High impacting Vivos Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VVOS
News
- Vivos Therapeutics announces up to $50M mixed shelf offering [Seeking Alpha]Seeking Alpha
- Trapped in CPAP Dependency? Vivos Liberates OSA Patients with Non-Invasive SolutionPR Web
- Recognizing Sleep as the Sixth Vital Sign: How Vivos Is Redefining Health CarePR Web
- Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswire
VVOS
Earnings
- 11/14/24 - Beat
VVOS
Sec Filings
- 2/14/25 - Form 424B5
- 2/14/25 - Form 8-K
- 2/11/25 - Form S-3
- VVOS's page on the SEC website